Overview

Ipilimumab is a monoclonal antibody that blocks CTLA-4, a checkpoint protein on T cells. By releasing this brake on the immune response, it enables a broader anti-tumor attack than T cells would mount unaided. Approved first in 2011 for melanoma, its role has expanded across several tumor types, often in combination with the PD-1 inhibitor nivolumab.

Melanoma and Adjuvant Use

In melanoma, ipilimumab is used for unresectable or metastatic disease, as a single agent or with nivolumab, and as adjuvant therapy after complete resection of nodal disease. This breadth makes it relevant both for advanced disease and for reducing the risk of recurrence in surgically treated patients.

Genomically Defined Populations

A particularly distinctive population is microsatellite instability-high or mismatch repair deficient colorectal cancer, where ipilimumab with nivolumab is used regardless of tissue site. Similarly, non-small cell lung cancer cohorts are selected by PD-L1 expression and the absence of EGFR or ALK aberrations, showing how biomarker testing shapes eligibility.

Other Approved Combinations

Beyond these, ipilimumab with nivolumab is approved in intermediate- or poor-risk advanced renal cell carcinoma, in hepatocellular carcinoma as first-line and after prior sorafenib, in malignant pleural mesothelioma, and in esophageal squamous cell carcinoma expressing PD-L1. Each indication pairs the CTLA-4 blockade with a partner regimen and a defined line of therapy.

Safety Considerations That Shape Prescribing

Because ipilimumab amplifies immune activity, it can produce immune-related adverse events affecting the skin, intestine, liver, or endocrine organs. These toxicities require early recognition and, in some cases, immunosuppression, which is why combination regimens are used within defined protocols. The benefit-risk discussion therefore differs by indication and by whether the patient is treatment-naive or heavily pretreated. Prescribers weigh these factors alongside the specific biomarker and line of therapy before starting treatment. Patient education about symptom reporting is a practical part of safe use, since delays in managing immune toxicity can be serious.

FAQ

Q: Is ipilimumab used alone or only in combinations? A: It is used both ways; many current indications combine it with nivolumab, while some melanoma settings still use it as a single agent or as adjuvant therapy.

Q: Why are biomarker tests required for some populations? A: Tests such as PD-L1 or microsatellite instability status identify the subgroups most likely to benefit and are part of the approved use.

Q: Which patients receive it after other treatments? A: Several indications, including hepatocellular carcinoma after sorafenib, specify prior therapy, whereas others use the combination as a first-line option.